's "Just Do It" tagline usually isn't great advice for investors. It's smart to conduct solid research on a stock before buying. That said, some outliers are so promising that spending a lot of time in analysis isn't so necessary.

Three Motley Fool contributors believe they've identified such exceptions. Here's why they think Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer growth stocks to buy in December.

David Jagielski (Eli Lilly): Eli Lilly is becoming a beast in the healthcare industry. Its market cap is up to $560 billion, and the stock trades at more than 100 times its trailing earnings. Yet, despite such an astronomical valuation, this is a no-brainer investment.

Continue reading

Source Fool.com